Polyclonal antibody-induced downregulation of HER1/EGFR and HER2 surpasses the effect of combinations of specific registered antibodies

Polyclonal antibody-induced downregulation of HER1/EGFR and HER2 surpasses the effect of combinations of specific registered antibodies

BackgroundAntitumor therapies targeting HER1/EGFR and HER2, such as monoclonal antibodies (MAbs) and tyrosine-kinase inhibitors (TKIs), have demonstrated a significant clinical benefit, but the emergence of resistance limits long-term efficacy. While secondary HER1 mutations confer tolerance to TKI,...

Full description

Bibliographic Details
Main Authors: Gretchen Bergado-Báez, Narjara Gonzalez Suarez, Lisset Chao García, Dayana Pérez-Martínez, Diana Rosa Hernández-Fernández, Talia Fundora-Barrios, Antonio Rodríguez-Álvarez, Geidy Diana Díaz-Ordaz, Moshit Lindzen, Yosef Yarden, Belinda Sánchez-Ramírez
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-11-01
Series:Frontiers in Oncology
Subjects:
HER1
HER2
resistance
polyclonal antibodies
monoclonal antibodies
receptor degradation
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.951267/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.951267/full

Similar Items